Skip to main content

Articles

Page 27 of 27

  1. The use of race in biomedical research has, for decades, been a source of social controversy. However, recent events, such as the adoption of racially targeted pharmaceuticals, have raised the profile of the r...

    Authors: Timothy Caulfield, Stephanie M Fullerton, Sarah E Ali-Khan, Laura Arbour, Esteban G Burchard, Richard S Cooper, Billie-Jo Hardy, Simrat Harry, Robyn Hyde-Lay, Jonathan Kahn, Rick Kittles, Barbara A Koenig, Sandra SJ Lee, Michael Malinowski, Vardit Ravitsky, Pamela Sankar…

    Citation: Genome Medicine 2009 1:8

    Content type: Correspondence

    Published on:

  2. The Genetic Information Nondiscrimination Act of 2008 (GINA) was recently enacted in the United States. Its supporters have applauded the passage of GINA, and they hope that it will alleviate public fear about...

    Authors: Amy L McGuire and Mary Anderlik Majumder

    Citation: Genome Medicine 2009 1:6

    Content type: Commentary

    Published on:

  • Editorial Board
  • Editorial Team
  • Sign up for article alerts and news from this journal
  • Contact us
  • Announcements

    C19 Rapid Review initiative

    Genome Medicine has joined the C19 Rapid Review initiative, a cross-publisher collaboration to ensure that COVID-19 research is reviewed and published as quickly and openly as possible. Learn more here

    Submissions from medRxiv 

    Authors are now able to submit manuscripts to Genome Medicine directly from medRxiv without having to re-upload files.

    Portable peer review

    To reduce time spent on serial submissions and iterative reviewing, Genome Medicine offers to consider manuscripts on the basis of reviews received at other journals. We also support transfers of reviews obtained at Genome Medicine to other journals, including those outside of BMC and Springer Nature. Learn more from our peer review policy page.

    COVID-19 submissions

    In response to the current SARS-CoV-2 pandemic Genome Medicine editors will treat relevant submissions with high priority.